Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10236401 | 1.00 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2BTKHRH3POLB | |
| SCHEMBL8120922 | 0.91 | HSD17B10 (0.51) | HSD17B10SMN1; SMN2BTKPOLBCHRM2 | |
| SCHEMBL7874236 | 0.87 | SMN1; SMN2 (0.40) | HSD17B10SMN1; SMN2HRH3POLBCHRM2 | |
| SCHEMBL2680322 | 0.87 | SMN1; SMN2 (0.40) | HSD17B10SMN1; SMN2HRH3POLBCHRM2 | |
| SCHEMBL1198433 | 0.86 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2BTKHRH3POLB | |
| SCHEMBL13481736 | 0.86 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2BTKHRH3POLB | |
| SCHEMBL3194210 | 0.86 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2BTKHRH3POLB | |
| SCHEMBL408875 | 0.82 | SMN1; SMN2 (0.44) | HSD17B10SMN1; SMN2BTKPOLBCHRM2 | |
| SCHEMBL5505807 | 0.82 | SMN1; SMN2 (0.44) | HSD17B10SMN1; SMN2BTKPOLBCHRM2 | |
| SCHEMBL3240371 | 0.82 | SMN1; SMN2 (0.41) | HSD17B10SMN1; SMN2POLBCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | HSD17B10 3617/4885SMN1; SMN2 1798/4885BTK 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.